- Home
- STCN vs IKNA Comparison
STCN vs IKNA Comparison
Compare STCN & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- IKNA
- Stock Information
- Founded
- STCN 1986
- IKNA 2016
- Country
- STCN United States
- IKNA United States
- Employees
- STCN N/A
- IKNA N/A
- Industry
- STCN Advertising
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- STCN Consumer Discretionary
- IKNA Health Care
- Exchange
- STCN Nasdaq
- IKNA Nasdaq
- Market Cap
- STCN 63.4M
- IKNA 83.0M
- IPO Year
- STCN 1994
- IKNA 2021
- Fundamental
- Price
- STCN $10.40
- IKNA $1.68
- Analyst Decision
- STCN
- IKNA Buy
- Analyst Count
- STCN 0
- IKNA 2
- Target Price
- STCN N/A
- IKNA $3.00
- AVG Volume (30 Days)
- STCN 11.9K
- IKNA 41.6K
- Earning Date
- STCN 12-12-2024
- IKNA 11-07-2024
- Dividend Yield
- STCN N/A
- IKNA N/A
- EPS Growth
- STCN 203.29
- IKNA N/A
- EPS
- STCN 3.17
- IKNA N/A
- Revenue
- STCN $169,044,000.00
- IKNA $1,844,000.00
- Revenue This Year
- STCN N/A
- IKNA N/A
- Revenue Next Year
- STCN N/A
- IKNA N/A
- P/E Ratio
- STCN $3.19
- IKNA N/A
- Revenue Growth
- STCN N/A
- IKNA N/A
- 52 Week Low
- STCN $7.36
- IKNA $1.02
- 52 Week High
- STCN $13.00
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- STCN 57.19
- IKNA 51.57
- Support Level
- STCN $9.90
- IKNA $1.68
- Resistance Level
- STCN $10.29
- IKNA $1.78
- Average True Range (ATR)
- STCN 0.39
- IKNA 0.04
- MACD
- STCN 0.11
- IKNA 0.00
- Stochastic Oscillator
- STCN 100.00
- IKNA 36.36
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.